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Burnout or depression: 
both individual and 
social issue
In view of the profound problems 
attached to the construct of burnout, we 
recommended in our Correspondence 
(April 8, p 1397)1 that occupational 
health specialists focus on (job-related) 
depression rather than burnout to help 
workers more effectively. In a reply to 
our letter, Ronald Epstein and Michael 
Privitera (April 8, 1398)2 rejected our 
recommendation on the grounds that 
burnout is not a “purely individual 
syndrome”. The authors further argued 
that “considering burnout solely as a 
mental illness of individual workers 
rather than work-related distress would 
be disastrous”. Problematically, Epstein 
and Privitera attributed to us an idea 
that is not ours. In these authors’ view, 
equating burnout with depression 
is synonymous with mistakenly 
individualising a social problem. In 
our estimation, the argument that 
depression cannot replace burnout 
because burnout is a social problem 
whereas depression is an individual 
problem is specious and part of a 
false debate.
First, the phenomena of interest 
(burnout or depression) should not 
be confused with the perspectives 
(individual or social) adopted to 
elucidate those phenomena. Second, 
both burnout and depression are best 
explained through the interaction 
of social or external conditions with 
individual or internal dispositions.3,4 
Unresolvable stress—the putative 
cause of burnout—has a key role in the 
aetiology of depression in individuals 
with no noticeable susceptibility to 
depression.3 Crucially, in human beings, 
most sources of stress are rooted in 
social life (eg, work). Therefore, social 
factors are central to the development 
of depressive symptoms or disorders.4 
Depression can be job-related.4,5 While 
leaving our recommendation intact, 
the authors’ argument allows us to 
address an objection that is commonly 
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